Io Therapeutics, Inc., presented data from studies of IRX4204
Io Therapeutics, Inc., presented data from studies of IRX4204, the company's phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease
SPRING, Texas, July 09, 2024 (GLOBE NEWSWIRE) - Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson's disease (PD), and Alzheimer's disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204. IRX4204 is a highly potent and highly selective, orally available, brain penetrant, third generation RXR agonist compound which has been tested in early phase clinical trials in patients with Parkinson's disease or cancers. The presentation titled “The highly potent and selective RXR agonist compound IRX4204 is a potential treatment for normal aging-related neurodegeneration, Parkinson's disease (PD), and Alzheimer's disease (AD)” was delivered at the Federation of American Societies for Experimental Biology (FASEB) Seventh International Conference on Retinoids, being held in St. Paul, Minnesota, USA. The presentation was authored by Vidyasagar Vuligonda, Ph.D., Chief Science Officer of the company and inventor of IRX4204, and Martin E. Sanders, M.D., the company's Chief Executive Officer.
Normal aging-related neurodegeneration has been reported to be substantially related to chronic low-grade inflammation in the brain, so called neuro-inflammaging. Neuro-inflammaging results in chronic loss of myelinated nerve fibers, causing disruption of functional neuroelectrical connections between neurons in various parts of the brain. Chronic neuro-inflammaging eventually leads to death of neurons. These neurodegenerative processes produce loss of memory and cognitive functions, and other functional disabilities in patients with normal brain aging, and in diverse types of neurological conditions including PD, and AD.
Neuro-inflammaging is related to imbalance of immunosuppressive T-regulatory cells (Treg) with pro-inflammatory cytokine interleukin-17 (IL-17) overproducing T-cells (Th17) in the brain. Neuro-inflammaging also is related to overactivity of brain microglia, which produce the pro-inflammatory cytokine interleukin-6 (IL-6), and other pro-inflammatory factors.
Parkinson's disease (PD) and Alzheimer's disease (AD) brains manifest similar neuro-inflammaging pathologies to those observed in normal brain aging, but also have distinct pathologies related to deposition of abnormal misfolded proteins such as alpha synuclein in PD, and beta amyloid in AD. It is generally accepted within the neurodegenerative diseases research community that neuro-inflammaging establishes an at-risk environment within the brain, that may increase vulnerability for development of PD, AD, and other neurodegenerative diseases.
The presented studies showed that IRX4204 promotes differentiation and growth of immunosuppressive human Tregs, and inhibits differentiation of pro-inflammatory human Th17 cells, while reducing production of IL-17. IRX4204 also inhibits production by microglia of IL-6 and other pro-inflammatory factors. In addition, IRX4204 promotes differentiation and growth of myelin-producing oligodendrocytes in vitro and promotes myelinated nerve fiber protection and repair (remyelination) in mouse models of demyelination. IRX4204 demonstrated direct beneficial effects alone, and additively in combination with insulin, or thyroid hormone on cortical neurons in vitro, promoting neurite outgrowth, a neuro-reparative mechanism by which damaged neurons may re-establish function-preserving connections with other neurons. These findings support the potential for IRX4204 protecting against or even reversing neuro-inflammaging-induced chronic loss of myelinated nerve fibers and neuronal damage in normal brain aging and neurodegenerative diseases.
Further demonstration of IRX4204 beneficial effects in neurodegeneration was provided by in vivo studies in rodent models of PD, and AD. IRX4204 effectively reduced motor deficits in a rat PD model while increasing dopaminergic neuron survival in the rat brains. In a transgenic beta amyloid mouse model of AD, IRX4204 decreased deposition of new beta amyloid in the mouse brains while preserving memory functions in the mice.
IRX4204 has demonstrated safety and tolerability of oral dosing in phase I and II clinical trials in 85 patients with various cancers and 15 patients with PD for up to 20 months of continuous treatment. In PD patients, IRX4204 demonstrated brain penetrance, and improvement of motor functions in 13 of 15 patients in open label assessments. The company is planning to initiate a placebo-controlled phase II clinical trial of IRX4204 in Parkinson's disease patients in Q4 of 2024, to further demonstrate safety and efficacy in PD patients.
Dr. Vuligonda stated, “Our results identify a new approach to potentially slowing or reversing the neurodegeneration of normal aging, as well as treating the pathologic conditions of Parkinson's disease and Alzheimer's disease, which cause seriously disabling chronic decline of cognitive and other functional abilities.”
Dr. Sanders stated, “IRX4204 has been safe and well tolerated in patients and has potential to be an effective monotherapy for prevention or treatment of debilitating neurologic manifestations associated with normal aging, Parkinson's disease, Alzheimer's disease and other neurologic conditions. In addition, IRX4204 provides opportunities for future development of combination treatments with even greater efficacy for these conditions, by administering IRX4204 with other generally well-tolerated and already available agents, such as insulin, GLP-1 agonists, other neurotrophic factors, thyroid hormone, or anti-beta amyloid monoclonal antibodies. We believe multi-agent combination treatments including IRX4204 will enable development of well tolerated, highly effective preventative and therapeutic interventions for diverse types of neurodegenerative diseases.”
About Io Therapeutics: Io Therapeutics, Inc. is a privately held company headquartered in Spring, Texas. More information on Io Therapeutics and its product development programs is available on the company's web site: www.io-therapeutics.com
Forward Looking Statements: This news release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
Contact:
info@io-therapeutics.com
- 传播孝善爱,助力智慧康养,乾翔健康感恩五心操大赛圆满成功!
- The Brazilian Football Confederation and the International Centre for Sport Security signs at Wemble
- Constellation Brands to Report First Quarter Fiscal 2025 Financial Results; Host Conference Call Jul
- 【福州爱尔眼科】侧躺看书、玩手机,双眼度数相差越来越大,该怎么解决?
- 五丰黎红针对主厨开展精准营销,“星厨俱乐部”平台助力调味品快速动销。
- 张伟用老师受聘飞世界国际教育联盟美国访学专家顾问
- SLB宣布2024年第一季度业绩电话会议
- 九恒星新一代结算业务系统在晋煤财务公司焕新上线:智能化升级,实用性凸显
- 达因药业从拓荒到领跑,儿药“私人订制”扛旗者的三十年
- 盈美信科发布2023年消费者权益保护年报
- 平安人寿内蒙古分公司开展78全国保险公众宣传日活动
- 倍嵘证券以引进国际先进的金融理念和吸引更多外资资本进入
- Fortrea Launches AI Innovation Studio to Galvanize Technology and Human Solutions to Improve Clinica
- 泉州海峡抗衰届新晋C位,第二代半岛超声炮(黄金版)它来了
- 越秀·天玥|以美好立意,凝聚全家人的幸福向往
- 持续助力达沃斯!英领受邀为西岗区政府机关干部培训!
- At Our Ocean Conference, Global Fishing Watch welcomes international partnerships to enhance ocean m
- UK businesses must prioritise payment technology to build customer loyalty and stay competitive: New
- President Lula to Speak at FII PRIORITY Rio de Janeiro Summit at the Copacabana Palace Wednesday
- Ella陈嘉桦全新专辑预购夺冠!同名主打曲MV正式上线!
- 通过全球最严TGA认证,优思益打造全系列高品质健康产品
- 千寻位置:北斗时空智能应用融入大众生活,赋能产业形成新质生产力
- 数说论坛 |浪潮卓数大数据:基层一张表,为基层工作减负增效
- 中國最具影響力國寶級資深醫學專家——周廣宇
- 世界环境日丨拉普拉斯为共建清洁美丽世界助力
- 助力新型工业化,浪潮海岳软件应邀参加“工赋山东”2024山东工业互联网峰会
- 领先的影响力数据与分析提供商GIST Impact获得UBS Next的投资
- 第60届亚太影展启动征片
- Novotech 发布念珠菌病和类风湿关节炎临床试验概况报告,为生物技术研究规划提供支持
- 飘香腊八粥,浓浓仲景情|张仲景大药房在全省开展300多场腊八节免费送粥活动
推荐
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 奥运冠军刘翔更新社交账号晒出近照 时隔473天更新动态! 2月20日凌晨2点,奥运冠军刘翔更新社交账号晒 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯